Oral microbiome, COVID-19 and probiotics

1.      World health organization (WHO). WHO coronavirus (COVID-19) dashboard. [Internet] 2022. Available from: https://covid19.who.int/ [Accessed on 22 Apr 2022].

2.      Ye ZW, Yuan S, Yuen KS, Fung SY, Chan CP, Jin DY. Zoonotic origins of human coronaviruses. Int J Biol Sci 2020; 16(10): 1686–97.

3.      Łoniewski I, Skonieczna-Żydecka K, Sołek-Pastuszka J, Marlicz W. Probiotics in the management of mental and gastrointestinal post-COVID symptomes. J Clin Med 2022; 11(17): 5155.

4.      Baghbani T, Nikzad H, Azadbakht J, Izadpanah F, Haddad Kashani H. Dual and mutual interaction between microbiota and viral infections: a possible treat for COVID-19. Microb Cell Fact 2020; 19(1): 217.

5.      Soffritti I, D'Accolti M, Fabbri C, Passaro A, Manfredini R, Zuliani G, et al. Oral mycrobiome dysbiosis is associated with symptoms severity and local immune/inflammatory response in COVID-19 patients: a cross-sectional study. Front Microbiol 2021; 12: 687513.

6.      Bohórquez-Ávila S, Bernal-Cepeda L, Reina-Marin M, Navarro-Saiz L, Castellanos J. The mouth, oral health, and infection with SARS-CoV-2: an underestimated topic. Infectio 2022; 26 (1): 78–82.

7.      To KK, Tsang OT, Yip CC, Chan KH, Wu TC, Chan JM, et al. Consistent detection of 2019 novel coronavirus in saliva. Clin Infect Dis 2020; 71(15): 841–3.

8.      Amorim Dos Santos J, Normando AGC, Carvalho da Silva RL, De Paula RM, Cembranel AC, Santos-Silva AR, et al. Oral mucosal lesions in a COVID-19 patient: new signs or secondary manifestations? Int J Infect Dis 2020; 97: 326–8.

9.      Bao L, Zhang C, Dong J, Zhao L, Li Y, Sun J. Oral mycrobiome and SARS-CoV-2: beware of lung co-infection. Front Microbiol 2020; 11: 1840.

10.   Silva A, Azevedo M, Sampaio-Maia B, Sousa-Pinto B. The effect of mouthrinses on severe acute respiratory syndrome coronavirus 2 viral load: a systematic review. J Am Dent Assoc 2022: 635–48. [Epub ahead of print].

11.   Paradowska-Stolarz AM. Oral manifestations of COVID-19: brief review. Dent Med Probl 2021; 58(1): 123–6.

12.   Xu J, Li Y, Gan F, Du Y, Yao Y. Salivary glands: Potential reservoirs for COVID-19 asymptomatic infection. J Dent Res 2020; 99(8): 989.

13.   Mohapatra RK, Dhama K, Mishra S, Sarangi AK, Kandi V, Tiwari R, et al. The microbiota-related coinfections in COVID-19 patients: a real challenge. Beni Suef Univ J Basic Appl Sci 2021;10 (1): 47.

14.   Rocchi G, Giovanetti M, Benedetti F, Borsetti A, Ceccarelli G, Zella D, et al. Gut microbiota and COVID-19: potential implications for disease severity. Pathogens 2022; 11(9): 1050.

15.   Amrouche T, Chikindas ML. Probiotics for immunomodulation in prevention against respiratory viral infections with special emphasis on COVID-19. AIMS Microbiol 2022; 8(3): 338–56.

16.   Cyprian F, Sohail MU, Abdelhafez I, Salman S, Attique Z, Kamareddine L, et al. SARS-CoV-2 and immune-microbiome interactions: lessons from respiratory viral infections. Int J Infect Dis 2021; 105: 540–50.

17.   Rafiqul Islam SM, Foysal MJ, Hoque MN, Mehedi HMH, Rob MA, Salauddin A, et al. Dysbiosis of oral and gut microbiomes in SARS-CoV-2 infected patients in Bangladesh: elucidating the role of opportunistic gut microbes. Front Med (Lausanne) 2022; 9: 821777.

18.   Herrera D, Serrano J, Roldán S, Sanz M. Is the oral cavity relevant in SARS-CoV-2 pandemic? Clin Oral Investig 2020; 24(8): 2925–30.

19.   Zhao H, Chen S, Yang F, Wu H, Ba Y, Cui L, et al. Alternation of nasopharyngeal microbiota in healthy youth is associated with environmental factors: implication for respiratory diseases. Int J Environ Health Res 2022; 32(5): 952–62.

20.   Iebba V, Zanotta N, Campisciano G, Zerbato V, Di Bella S, Cason C, et al. Profiling of oral microbiota and cytokines in COVID-19 patients. Front Microbiol 2021; 12: 671813.

21.   Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA 2020; 323(11): 1061–9.

22.   Barros MIOS, Firmino GLO, Vieira T da S, Araujo A de A, Souza L de LB, Reis BS, et al. Oral manifestations associated with COVID-19 infection. RSD [Internet] 2021; [accessed on 19 Mar 2023] 10(16): e555101624107. Available from: https://rsdjournal.org/index.php/rsd/article/view/24107>

23.   Haran JP, Bradley E, Zeamer AL, Cincotta L, Salive MC, Dutta P, et al. Inflammation-type dysbiosis of the oral mycrobiome associates with the duration of COVID-19 symptoms and long COVID. JCI Insight 2021; 6(20): e152346.

24.   Ward DV, Bhattarai S, Rojas-Correa M, Purkayastha A, Holler D, Qu MD, et al. The intestinal and oral microbiomes are robust predictors of COVID-19 severity the main predictor of COVID-19-related fatality [preprint]. 2021; medRxiv: 2021.01.05.20249061. Available from: https://doi.org/doi:10.1101/2021.01.05.20249061

25.   Singh K, Rao A. Probiotics: a potential immunomodulator in COVID-19 infection management. Nutr Res 2021; 87: 1–12.

26.   Ursell LK, Metcalf JL, Parfrey LW, Knight R. Defining the human microbiome. Nutr Rev 2012; 70 (Suppl 1): S38–44.

27.   Santacroce L, Charitos IA, Ballini A, Inchingolo F, Luperto P, De Nitto E, et al. The human respiratory system and its microbiome at a glimpse. Biology (Basel) 2020; 9(10): 318.

28.   Santacroce L, Sardaro N, Topi S, Pettini F, Bottalico L, Cantore S, et al. The pivotal role of oral microbiota in health and disease. J Biol Regul Homeost Agents 2020; 34(2): 733–7.

29.   Gomez PAM. Use of probiotics in dentistry. Dent Oral Craniofac Res 2017; 4(1): 1–4.

30.   Lamont RJ, Koo H, Hajishengallis G. The oral microbiota: dynamic communities and host interactions. Nat Rev Microbiol 2018; 16(12): 745–59.

31.   Caselli E, Fabbri C, D'Accolti M, Soffritti I, Bassi C, Mazzacane S, et al. Defining the oral mycrobiome by whole-genome sequencing and resistome analysis: the complexity of the healthy picture. BMC Microbiol 2020; 20(1): 120.

32.   Radaic A, Kapila YL. The oralome and its dysbiosis: new insights into oral microbiome-host interactions. Comput Struct Biotechnol J 2021; 19: 1335–60.

33.   Wade WG. The oral mycrobiome in health and disease. Pharmacol Res 2013; 69(1): 137–43.

34.   Rowan-Nash AD, Korry BJ, Mylonakis E, Belenky P. Cross-domain and viral interactions in the microbiome. Microbiol Mol Biol Rev 2019; 83(1): e00044–18.

35.   Yamamoto S, Saito M, Tamura A, Prawisuda D, Mizutani T, Yotsuyanagi H. The human microbiome and COVID-19: a systematic review. PLoS One 2021; 16(6): e0253293.

36.   Biagi E, Candela M, Fairweather-Tait S, Franceschi C, Brigidi P. Aging of the human metaorganism: the microbial counterpart. Age (Dordr) 2012; 34(1): 247–67.

37.   Park SH, Kim KA, Ahn YT, Jeong JJ, Huh CS, Kim DH. Comparative analysis of gut microbiota in elderly people of urbanized towns and longevity villages. BMC Microbiol 2015; 15: 49.

38.   Arweiler NB, Netuschil L. The oral microbiota. Adv Exp Med Biol 2016; 902: 45–60.

39.   Brooks AW, Priya S, Blekhman R, Bordenstein SR. Gut microbiota diversity across ethnicities in the United States. PLoS Biol 2018; 16(12): e2006842.

40.   Rinninella E, Raoul P, Cintoni M, Franceschi F, Miggiano GAD, Gasbarrini A, et al. What is the healthy gut microbiota composition? A changing ecosystem across age, environment, diet, and diseases. Microorganisms 2019; 7(1): 14.

41.   Liu J, Lahousse L, Nivard MG, Bot M, Chen L, van Klinken JB, et al. Integration of epidemiologic, pharmacologic, genetic and gut microbiome data in a drug-metabolite atlas. Nat Med 2020; 26(1): 110–7.

42.   Boyajian JL, Ghebretatios M, Schaly S, Islam P, Prakash S. Microbiome and human aging: probiotic and prebiotic potentials in longevity, skin health and cellular senescence. Nutrients 2021; 13(12): 4550.

43.   Pérez-Brocal V, Moya A. The analysis of the oral DNA virome reveals which viruses are widespread and rare among healthy young adults in Valencia (Spain). PLoS One 2018; 13(2): e0191867.

44.   Baker JL, Bor B, Agnello M, Shi W, He X. Ecology of the oral microbiome: beyond bacteria. Trends Microbiol 2017; 25(5): 362–74.

45.   de la Cruz Peña MJ, Martinez-Hernandez F, Garcia-Heredia I, Lluesma Gomez M, Fornas Ò, Martinez-Garcia M. Deciphering the human virome with single-virus genomics and metagenomics. Viruses 2018; 10(3): 113.

46.   Peters BA, Wu J, Hayes RB, Ahn J. The oral fungal mycobiome: characteristics and relation to periodontitis in a pilot study. BMC Microbiol 2017; 17(1): 157.

47.   Mosaddad SA, Tahmasebi E, Yazdanian A, Rezvani MB, Seifalian A, Yazdanian M, et al. Oral microbial biofilms: an update. Eur J Clin Microbiol Infect Dis 2019; 38(11): 2005–19.

48.   Dubar M, Zaffino ML, Remen T, Thilly N, Cunat L, Machouart MC, et al. Protozoans in subgingival biofilm: clinical and bacterial associated factors and impact of scaling and root planing treatment. J Oral Microbiol 2019; 12(1): 1693222.

49.   Belmok A, de Cena JA, Kyaw CM, Damé-Teixeira N. The oral archaeome: a scoping review. J Dent Res 2020; 99(6): 630–43.

50.   Lu M, Xuan S, Wang Z. Oral microbiota: A new view of body health. Food Sci Hum Wellness 2019; 8(1): 8–15.

51.   Stubbendieck RM, May DS, Chevrette MG, Temkin MI, Wendt-Pienkowski E, Cagnazzo J, et al. Competition among nasal bacteria suggests a role for siderophore-mediated interactions in shaping the human nasal microbiota. Appl Environ Microbiol 2019; 85(10): e02406–18.

52.   Gebrayel P, Nicco C, Al Khodor S, Bilinski J, Caselli E, Comelli EM, et al.  Microbiota medicine: towards clinical revolution. J Transl Med 2022; 20(1): 111.

53.   Edwards V, Smith DL, Meylan F, Tiffany L, Poncet S, Wu WW, et al. Analyzing the role of gut microbiota on the onset of autoimmune diseases using TNF^ΔARE murine model. Microorganisms 2021; 10(1): 73.

54.   Petersen C, Round JL. Defining dysbiosis and its influence on host immunity and disease. Cell Microbiol 2014; 16(7): 1024–33.

55.   Nikolić-Jakoba N, Vojnović S, Pavić A, Janković S, Leković V, Vasiljević B. Polymerase chain reaction in the identification of periodontopathogens: a reliable and satisfactory method? Arch Biol Sci 2012; 64(4): 1413–23.

56.   Tandelilin RT, Widita E, Agustina D, Saini R. The effect of oral probiotic consumption on the caries risk factors among high-risk caries population. J Int Oral Health 2018; 10(3): 132–7.

57.   Zaura E, Twetman S. Critical appraisal of oral pre- and probiotics for caries prevention and care. Caries Res 2019; 53(5): 514–26. https://doi.org/10.1159/000499037. PMid: 30947169

58.   Ayala LDO, Zambrano JFB, Vire JMY, Gavilanes MPP, Coyago M de LR. Modulation of oral biofilm and immune response associated to mucosa with probiotic bacteria as a potential approach in the prevention of dental caries: a systematic review. Dent Oral Biol Craniofac Res 2020; 3(5): 1–7.

59.   Talaat D. Effect of probiotic chewable tablets on oral health and white spot lesions in pre-school children: a randomized clinical trial. Egypt Dent J 2021; 67(3): 1797–807.

60.   Milićević R, Brajović G, Nikolić-Jakoba N, Popović B, Pavlica D, Leković V, et al. Identification of periodontopathogen microorganisms by PCR technique. Srp Arh Celok Lek 2008; 136(9–10): 476–80. (Serbian)

61.   Kumar PS. From focal sepsis to periodontal medicine: a century of exploring the role of the oral mycrobiome in systemic disease. J Physiol 2017; 595(2): 465–76.

62.   Allaker RP, Stephen AS. Use of probiotics and oral health. Curr Oral Health Rep 2017; 4(4): 309–18.

63.   Radović N, Nikolić-Jakoba N, Petrović N, Milosavljević A, Brković B, Roganović J. MicroRNA-146a and microRNA-155 as novel crevicular fluid biomarkers for periodontitis in nondiabetic and type 2 diabetic patients. J Clin Periodontol 2018; 45(6): 663–71.

64.   Ratna Sudha M, Neelamraju J, Surendra Reddy M, Kumar M. Evaluation of the effect of probiotic Bacillus coagulans unique IS2 on mutans Streptococci and Lactobacilli levels in saliva and plaque: a double-blind, randomized, placebo-controlled study in children. Int J Dent 2020; 2020: 8891708.

65.   Wang L, Ganly I. The oral mycrobiome and oral cancer. Clin Lab Med 2014; 34(4): 711–9.

66.   Li Y, He J, He Z, Zhou Y, Yuan M, Xu X, et al. Phylogenetic and functional gene structure shifts of the oral microbiomes in periodontitis patients. ISME J 2014; 8(9): 1879–91.

67.   Abusleme L, Morandini AC, Hashizume-Takizawa T, Sahingur SE. Editorial: Oral mycrobiome and inflammation connection to systemic health. Front Cell Infect Microbiol 2021; 11: 780182.

68.   Qin J, Li Y, Cai Z, Li S, Zhu J, Zhang F, et al. A metagenome-wide association study of gut microbiota in type 2 diabetes. Nature 2012; 490(7418): 55–60.

69.   Marchi-Alves LM, Freitas D, de Andrade D, de Godoy S, Toneti AN, Mendes IAC. Characterization of oral microbiota in removable dental prosthesis users: influence of arterial hypertension. Biomed Res Int 2017; 2017: 3838640.

70.   Bryan NS, Tribble G, Angelov N. Oral mycrobiome and nitric oxide: the missing link in the management of blood pressure. Curr Hypertens Rep 2017; 19(4): 33.

71.   Cobb CM, Kelly PJ, Williams KB, Babbar S, Angolkar M, Derman RJ. The oral mycrobiome and adverse pregnancy outcomes. Int J Womens Health 2017; 9: 551–9.

72.   Chen C, Hemme C, Beleno J, Shi ZJ, Ning D, Qin Y, et al. Oral microbiota of periodontal health and disease and their changes after nonsurgical periodontal therapy. ISME J 2018; 12(5): 1210–24.

73.   Kaul D, Rathnasinghe R, Ferres M, Tan GS, Barrera A, Pickett BE, et al. Microbiome disturbance and resilience dynamics of the upper respiratory tract during influenza A virus infection. Nat Commun 2020; 11(1): 2537.

74.   Lee HS, Lobbestael E, Vermeire S, Sabino J, Cleynen I. Inflammatory bowel disease and Parkinson's disease: common pathophysiological links. Gut 2021; 70(2): 408–17.

75.   Willmott T, McBain AJ, Humphreys GJ, Myers J, Cottrell E. Does the oral mycrobiome play a role in hypertensive pregnancies? Front Cell Infect Microbiol 2020; 10: 389.

76.   Sohail MU, Hedin L, Al-Asmakh M. Dysbiosis of the salivary microbiome is associated with hypertension and correlated with metabolic syndrome biomarkers. Diabetes Metab Syndr Obes 2021; 14: 4641–53.

77.   Milasin J, Nikolić-Jakoba N, Stefanović D, Sopta J, Pucar A, Leković V, et al. Periodontal inflammation as risk factor for pancreatic diseases. In: Nagal A, editor. Inflammatory diseases - a modern perspective. London: IntechOpen; 2011.

78.   Đorđević V, Jovanović M, Stefanović V, Nikolić Jakoba N, Đokić G, Stašević Karličić I, et al. Assessment of periodontal health among the inpatients with schizophrenia. Vojnosanit Pregl 2019; 76(11): 1139–46.

79.   Ren Z, Wang H, Cui G, Lu H, Wang L, Luo H, et al. Alterations in the human oral and gut microbiomes and lipidomics in COVID-19. Gut 2021; 70(7): 1253–65.

80.   Zhang X, Zhang D, Jia H, Feng Q, Wang D, Liang D, et al. The oral and gut microbiomes are perturbed in rheumatoid arthritis and partly normalized after treatment. Nat Med 2015; 21(8): 895–905.

81.   Kurt BS, Ilhan B, Sevki BI, Kurt AF, Orhan K. Periodontal management during COVID-19 pandemic: mini review. Balk J Dent Med 2021; 25(3): 135–8.

82.   Rakić M, Nikolić-Jakoba N, Struillout X, Petković-Ćurčin A, Stamatović N, Matić S, et al. Receptor activator of nuclear factor kappa B (RANK) as a determinant of peri-implantitis. Vojnosanit Pregl 2013; 70(4): 346–51.

83.   Kilian M, Chapple IL, Hannig M, Marsh PD, Meuric V, Pedersen AM, et al. The oral mycrobiome - an update for oral healthcare professionals. Br Dent J 2016; 221(10): 657–66.

84.   Belkaid Y, Hand TW. Role of the microbiota in immunity and inflammation. Cell 2014; 157(1): 121–41.

85.  Trompette A, Gollwitzer ES, Pattaroni C, Lopez-Mejia IC, Riva E, Pernot J, et al. Dietary fiber confers protection against flu by shaping Ly6c- patrolling monocyte hematopoiesis and CD8+ T cell metabolism. Immunity 2018; 48(5): 992–1005. e8.

86.   Willis JR, Gabaldón T. The human oral mycrobiome in health and disease: from sequences to ecosystems. Microorganisms 2020; 8(2): 308.

87.   Lynch SV. Viruses and microbiome alterations. Ann Am Thorac Soc 2014; 11(Suppl 1): S57–60.

88.   Li N, Ma WT, Pang M, Fan QL, Hua JL. The commensal microbiota and viral infection: a comprehensive review. Front Immunol 2019; 10: 1551.

89.   Scannapieco FA. Role of oral bacteria in respiratory infection. J Periodontol 1999; 70(7): 793–802.

90.   Khan R, Petersen FC, Shekhar S. Commensal Bacteria: An emerging player in defense against respiratory pathogens. Front Immunol 2019; 10: 1203.

91.   Pfeiffer JK, Sonnenburg JL. The intestinal microbiota and viral susceptibility. Front Microbiol 2011; 2: 92.

92.   Hanada S, Pirzadeh M, Carver KY, Deng JC. Respiratory viral infection-induced microbiome alterations and secondary bacterial pneumonia. Front Immunol 2018; 9: 2640.

93.   Ai JW, Zhang HC, Xu T, Wu J, Zhu M, Yu YQ, et al. Optimizing diagnostic strategy for novel coronavirus pneumonia, a multi-center study in Eastern China [preprint]. 2020; medRxiv:2020.02.13.20022673. Available from: https://www.medrxiv.org/content/10.1101/2020.02.13.20022673v1

94.   Xu K, Cai H, Shen Y, Ni Q, Chen Y, Hu S, et al. Management of COVID-19: the Zhejiang experience. Zhejiang Da Xue Xue Bao Yi Xue Ban 2020; 49(2): 147–57. (Chinese)

95.   Cox MJ, Loman N, Bogaert D, O'Grady J. Co-infections: potentially lethal and unexplored in COVID-19. Lancet Microbe 2020; 1(1): e11.

96.   Roncati L, Lusenti B, Nasillo V, Manenti A. Fatal SARS-CoV-2 coinfection in course of EBV-associated lymphoproliferative disease. Ann Hematol 2020; 99(8):1945–6.

97.   Chakraborty S. Metagenome of SARS-Cov-2 patients in Shenzhen with travel to Wuhan shows a wide range of species - Lautropia, Cutibacterium, Haemophilus being most abundant - and Campylobacter explaining diarrhea [preprint]. OSF Preprints 2020; doi: 10.31219/osf.io/jegwq.

98.   Wu F, Zhao S, Yu B, Chen YM, Wang W, Song ZG, et al. A new coronavirus associated with human respiratory disease in China. Nature 2020; 579(7798): 265–9. Erratum in: Nature 2020; 580(7803): E7.

99.   Chen T, Song J, Liu H, Zheng H, Chen C. Positive Epstein-Barr virus detection in coronavirus disease 2019 (COVID-19) patients. Sci Rep 2021; 11(1): 10902.

100.               Yeoh YK, Zuo T, Lui GC, Zhang F, Liu Q, Li AY, et al. Gut microbiota composition reflects disease severity and dysfunctional immune responses in patients with COVID-19. Gut 2021; 70(4): 698–706.

101.               Marouf N, Cai W, Said KN, Daas H, Diab H, Chinta VR, et al. Association between periodontitis and severity of COVID-19 infection: a case-control study. J Clin Periodontol 2021; 48(4): 483–91.

102.               Song WJ, Hui CKM, Hull JH, Birring SS, McGarvey L, Mazzone SB, et al. Confronting COVID-19-associated cough and the post-COVID syndrome: role of viral neurotropism, neuroinflammation, and neuroimmune responses. Lancet Respir Med 2021; 9(5): 533–44.

103.               Oronsky B, Larson C, Hammond TC, Oronsky A, Kesari S, Lybeck M, et al. A review of persistent post-COVID syndrome (PPCS). Clin Rev Allergy Immunol 2023; 64(1): 66–74; Epub 2021; 20: 1–9.

104.               France K, Glick M. Long COVID and oral health care considerations. J Am Dent Assoc 2022; 153(2): 167–74.

105.               Larsen JM. The immune response to Prevotella bacteria in chronic inflammatory disease. Immunology 2017; 151(4): 363–74.

106.               Xu L, Chen X, Wang Y, Jiang W, Wang S, Ling Z, et al. Dynamic alterations in salivary microbiota related to dental caries and age in preschool children with deciduous dentition: a 2-year follow-up study. Front Physiol 2018; 9: 342.

107.               Khan AA, Khan Z. COVID-2019-associated overexpressed Prevotella proteins mediated host-pathogen interactions and their role in coronavirus outbreak. Bioinformatics 2020; 36(13): 4065–9.

108.               Wu Y, Cheng X, Jiang G, Tang H, Ming S, Tang L, et al. Author correction: Altered oral and gut microbiota and its association with SARS-CoV-2 viral load in patients with COVID-19 during hospitalization. NPJ Biofilms Microbiomes 2021; 7(1): 90. Erratum for: NPJ Biofilms Microbiomes 2021; 7(1): 61.

109.               Jasinski-Bergner S, Mandelboim O, Seliger B. Molecular mechanisms of human herpes viruses inferring with host immune surveillance. J Immunother Cancer 2020; 8(2): e000841.

110.               Azarpazhooh A, Leake JL. Systematic review of the association between respiratory diseases and oral health. J Periodontol 2006; 77(9): 1465–82.

111.               Hols P, Ledesma-García L, Gabant P, Mignolet J. Mobilization of microbiota commensals and their bacteriocins for therapeutics. Trends Microbiol 2019; 27(8): 690–702.

112.               Barbour A, Wescombe P, Smith L. Evolution of Lantibiotic Salivaricins: New weapons to fight infectious diseases. Trends Microbiol 2020; 28(7): 578–93.

113.               Hadžić Z, Pašić E, Gojkov-Vukelić M, Hadžić S. Effects of Lactobacillus reuteri lozenges (Prodentis) as adjunctive therapeutic agent in non-surgical therapy of periodontitis. Balk J Dent Med 2021; 25(1): 41–5.

114.               Bottari B, Castellone V, Neviani E. Probiotics and Covid-19. Int J Food Sci Nutr 2021; 72(3): 293–9.

115.               Mikulicic A, Bakarcic D, Ivancic Jokic N, Hrvatin S, Culav T. The use of probiotics in dental medicine. Madridge J Dent Oral Surg 2017; 2(1): 44–6.

116.               Bermudez-Brito M, Plaza-Díaz J, Muñoz-Quezada S, Gómez-Llorente C, Gil A. Probiotic mechanisms of action. Ann Nutr Metab 2012; 61(2): 160–74.

117.               Eguchi K, Fujitani N, Nakagawa H, Miyazaki T. Prevention of respiratory syncytial virus infection with probiotic lactic acid bacterium Lactobacillus gasseri SBT2055. Sci Rep 2019; 9(1): 4812.

118.               Moravvej H, Memariani H, Memariani M. Therapeutic and preventive potential of probiotics against COVID-19. Res Bull Med Sci 2020; 25(1): e18.

119.               Azad MAK, Sarker M, Wan D. Immunomodulatory effects of probiotics on cytokine profiles. Biomed Res Int 2018; 2018: 8063647.

120.               Hardy H, Harris J, Lyon E, Beal J, Foey AD. Probiotics, prebiotics and immunomodulation of gut mucosal defences: homeostasis and immunopathology. Nutrients 2013; 5(6): 1869–912.

121.               Al Kassaa I. The antiviral activity of probiotic metabolites. In: Al Kassaa I. New insights on antiviral probiotics. Springer, Cham: 2017; 83–97.

122.               Xia Y, Cao J, Wang M, Lu M, Chen G, Gao F, et al. Effects of Lactococcus lactis subsp. lactis JCM5805 on colonization dynamics of gut microbiota and regulation of immunity in early ontogenetic stages of tilapia. Fish Shellfish Immunol 2019; 86: 53–63.

123.               Hung YP, Lee CC, Lee JC, Tsai PJ, Ko WC. Gut dysbiosis during COVID-19 and potential effect of probiotics. Microorganisms 2021; 9(8): 1605.

124.               Al Kassaa I, Hober D, Hamze M, Chihib NE, Drider D. Antiviral potential of lactic acid bacteria and their bacteriocins. Probiotics Antimicrob Proteins 2014; 6(3–4): 177–85.

125.               Mahooti M, Abdolalipour E, Salehzadeh A, Mohebbi SR, Gorji A, Ghaemi A. Immunomodulatory and prophylactic effects of Bifidobacterium bifidum probiotic strain on influenza infection in mice. World J Microbiol Biotechnol 2019; 35(6): 91.

126.               Baindara P, Chakraborty R, Holliday ZM, Mandal SM, Schrum AG. Oral probiotics in coronavirus disease 2019: connecting the gut-lung axis to viral pathogenesis, inflammation, secondary infection and clinical trials. New Microbes New Infect 2021; 40: 100837.

127.               Małaczewska J, Kaczorek-Łukowska E, Wójcik R, Siwicki AK. Antiviral effects of nisin, lysozyme, lactoferrin and their mixtures against bovine viral diarrhoea virus. BMC Vet Res 2019; 15(1): 318.

128.               Di Pierro F. A possible probiotic (S. salivarius K12) approach to improve oral and lung microbiotas and raise defenses against SARS-CoV-2. Minerva Med 2020; 111(3): 281–3.

129.               Zhang H, Yeh C, Jin Z, Ding L, Liu BY, Zhang L, et al. Prospective study of probiotic supplementation results in immune stimulation and improvement of upper respiratory infection rate. Synth Syst Biotechnol 2018; 3(2): 113–20.

130.              Seminario-Amez M, López-López J, Estrugo-Devesa A, Ayuso-Montero R, Jané-Salas E. Probiotics and oral health: a systematic review. Med Oral Patol Oral Cir Bucal 2017; 22(3): e282–8.

131.               Conte L, Toraldo DM. Targeting the gut-lung microbiota axis by means of a high-fibre diet and probiotics may have anti-inflammatory effects in COVID-19 infection. Ther Adv Respir Dis 2020; 14: 1753466620937170.

132.               Olaimat AN, Aolymat I, Al-Holy M, Ayyash M, Abu Ghoush M, Al-Nabulsi AA, et al. The potential application of probiotics and prebiotics for the prevention and treatment of COVID-19. NPJ Sci Food 2020; 4: 17.

133.               Stavropoulou E, Bezirtzoglou E. Probiotics in medicine: a long debate. Front Immunol 2020; 11: 2192.

134.               Xavier-Santos D, Padilha M, Fabiano GA, Vinderola G, Gomes Cruz A, Sivieri K, et al. Evidences and perspectives of the use of probiotics, prebiotics, synbiotics, and postbiotics as adjuvants for prevention and treatment of COVID-19: a bibliometric analysis and systematic review. Trends Food Sci Technol 2022; 120: 174–92. Erratum in: Trends Food Sci Technol 2022; 121: 156–160.

135.               d'Ettorre G, Ceccarelli G, Marazzato M, Campagna G, Pinacchio C, Alessandri F, et al. Challenges in the management of SARS-CoV2 infection: the role of oral bacteriotherapy as complementary therapeutic strategy to avoid the progression of COVID-19. Front Med (Lausanne) 2020; 7: 389.

136.               Tang H, Bohannon L, Lew M, Jensen D, Jung SH, Zhao A, et al. Randomised, double-blind, placebo-controlled trial of probiotics to eliminate COVID-19 transmission in exposed household contacts (PROTECT-EHC): a clinical trial protocol. BMJ Open 2021; 11(5): e047069.

137.               Endam LM, Tremblay C, Filali A, Desrosiers MY. Intranasal application of Lactococcus lactis W136 bacteria early in SARS-CoV-2 infection may have a beneficial immunomodulatory effect: A proof-of-concept study [preprint]. 2021; medRxiv: 2021.01.05.20249061. Available from: https://www.medrxiv .org/content/10.1101/2021.04.18.21255699v1.full

138.               Gutierrez-Castrellon P, Gandara-Martí T, Abreu AT, Nieto-Rufino CD, Lopez- Orduna E, Jimenez-Escobar I, et al. Efficacy and safety of novel probiotic formulation in adult Covid19 outpatients: a randomized, placebo-controlled clinical trial [preprint]. 2021; medRxiv: 2021.05.20.21256954. Available from: https://www.medrxiv.org/content/10.1101/2021.05.20.21256954v1.full.pdf+html

139.               Mozota M, Castro I, Gomez-Torres N, Arroyo R, Lailla Y, Somada M, et al. Administration of Ligilactobacillus salivarius MP101 in an elderly nursing home during the COVID-19 pandemic: immunological and nutritional impact. Foods 2021; 10(9): 2149.

140.               Wang Q, Lin X, Xiang X, Liu W, Fang Y, Chen H, et al.  Oropharyngeal probiotic ENT-K12 prevents respiratory tract infections among frontline medical staff fighting against COVID-19: a pilot study. Front Bioeng Biotechnol 2021; 9: 646184.

141.               Li M, He Z, Yang J, Guo Q, Weng H, Luo J, et al. Clinical characteristics, outcomes, and risk factors of disease severity in patients with COVID-19 and with a history of cerebrovascular disease in Wuhan, China: A Retrospective Study. Front Neurol 2022; 12: 706478.

142.               Bozkurt HS, Bilen Ö. Oral booster probiotic bifidobacteria in SARS-COV-2 patients. Int J Immunopathol Pharmacol 2021; 35: 20587384211059677.

143.               Wischmeyer PE, Tang H, Ren Y, Bohannon L, Ramirez ZE, Andermann TM, et al. Daily lactobacillus probiotic versus placebo in COVID-19-exposed household contacts (PROTECT-EHC): a randomized clinical trial [preprint]. 2022; medRxiv: 2022.01.04.21268275. Available from: https://www.medrxiv .org/content/10.1101/2022.01.04.21268275v1

144.               Block J. High risk COVID-19: potential intervention at multiple points in the COVID-19 disease process via prophylactic treatment with azithromycin or bee derived products. J Biomed Res Rev 2020; 3(1): 26–31.

145.               Horowitz RI, Freeman PR, Bruzzese J. Efficacy of glutathione therapy in relieving dyspnea associated with COVID-19 pneumonia: a report of 2 cases. Respir Med Case Rep 2020; 30: 101063.

146.               Pourhossein M, Moravejolahkami AR. Probiotics in viral infections, with a focus on COVID-19: a systematic review [preprint]. Authorea 2020; doi: 10.22541/au.158999387.76467979.

147.               Ceccarelli G, Borrazzo C, Pinacchio C, Santinelli L, Innocenti GP, Cavallari EN, et al. Oral bacteriotherapy in patients with COVID-19: a retrospective cohort study. Front Nutr 2021; 7: 613928.

148.               Patra S, Saxena S, Sahu N, Pradhan B, Roychowdhury A. Systematic network and meta-analysis on the antiviral mechanisms of probiotics: a preventive and treatment strategy to mitigate SARS-CoV-2 infection. Probiotics Antimicrob Proteins 2021;13(4): 1138–56.

149.               Ayyash M, Olaimat A, Al-Nabulsi A, Liu SQ. Bioactive properties of novel probiotic Lactococcus lactis fermented camel sausages: cytotoxicity, angiotensin converting enzyme inhibition, antioxidant capacity, and antidiabetic activity. Food Sci Anim Resour 2020; 40(2): 155–71.

150.               Nayebi A, Navashenaq JG, Soleimani D, Nachvak SM. Probiotic supplementation: a prospective approach in the treatment of COVID-19. Nutr Health 2022; 28(2): 163–75.

151.               Fernández-Fernández FJ. COVID-19, hypertension and angiotensin receptor-blocking drugs. J Hypertens 2020; 38(6): 1191.

152.               Imai Y, Kuba K, Rao S, Huan Y, Guo F, Guan B, et al. Angiotensin-converting enzyme 2 protects from severe acute lung failure. Nature 2005; 436(7047): 112–6.

153.               Spagnolello O, Pinacchio C, Santinelli L, Vassalini P, Innocenti GP, De Girolamo G, et al. Targeting microbiome: an alternative strategy for fighting SARS-CoV-2 infection. Chemotherapy 2021; 66(1–2): 24–32.

154.               Infusino F, Marazzato M, Mancone M, Fedele F, Mastroianni CM, Severino P, et al. Diet supplementation, probiotics, and nutraceuticals in SARS-CoV-2 infection: a scoping review. Nutrients 2020; 12(6): 1718.

155.               Santos TGFTD, Brito DHS, Santos NMVD, Paiva MC, Lyra MCA, Heimer MV, et al. Viral symptoms in children and SARS-COV-2: information for pediatric dentists for the control of transmission. Braz Oral Res 2022; 36: e029.